Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

Abstract: Formulations comprising anionic agents such as nucleic acids within a lipid-containing particle methods of formulating a lipid-containing particle comprising an anionic agent such as a nucleic acid, methods for preparing a lipid-containing particle comprising an anionic agent such as a nucleic acid, methods for therapeutic delivery of an anionic agent to a patient in need thereof, where the anionic agent is formulated in a lipid-containing particle as described herein.

Abstract: An agent, of a distributed intelligence application, generates feature data for a feature. A baseline configuration of parameters is processed, associated with the distributed intelligence application, to determine a first set of parameters. The baseline configuration of parameters and a modified configuration of parameters are processed to determine a second set of parameters. The modified configuration is associated with the distributed intelligence application and indicates a difference from the baseline configuration. A snapshot of dynamic data is processed according to an algorithm using the first set of parameters to determine a first result and using the second set of parameters to determine a second result. The first result and the second result are each provided with a respective indication of the configuration used to generate the result.

Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.

Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.

Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.

Abstract: Provided herein are double-stranded nucleic acid inhibitor molecules having a shortened sense strand with a stem loop structure and an antisense strand. Also provided are methods and compositions for reducing target gene expression and methods and compositions for treating a disease of interest.

Abstract: Formulations comprising anionic agents such as nucleic acids within a lipid-containing particle methods of formulating a lipid-containing particle comprising an anionic agent such as a nucleic acid, methods for preparing a lipid-containing particle comprising an anionic agent such as a nucleic acid, methods for therapeutic delivery of an anionic agent to a patient in need thereof, where the anionic agent is formulated in a lipid-containing particle as described herein.

Abstract: This disclosure relates to the use of RNA oligonucleotides, compositions and methods useful for reducing ALDH2 or other target gene expression, in the central nervous system. In some embodiments, the oligonucleotide is used in methods of treating neurological diseases. Stable oligonucleotide derivatives that have enhanced activity in the central nervous system are provided.

Abstract: A terminal includes a first connection section having a first connection central axis extending centrally though the first connection section along a longitudinal direction and a shoulder having a first surface extending normal to the longitudinal direction at an end of the first connection section. The shoulder has a width greater than the first connection section in a width direction perpendicular to the longitudinal direction and has a shoulder central axis extending centrally though the shoulder along the longitudinal direction. The shoulder central axis is offset from the first connection central axis in the width direction.

Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.

Abstract: A terminal includes a first connection section having a first connection central axis extending centrally though the first connection section along a longitudinal direction and a shoulder having a first surface extending normal to the longitudinal direction at an end of the first connection section. The shoulder has a width greater than the first connection section in a width direction perpendicular to the longitudinal direction and has a shoulder central axis extending centrally though the shoulder along the longitudinal direction. The shoulder central axis is offset from the first connection central axis in the width direction.

Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

Abstract: There is disclosed a dispenser 10 for dispensing product objects, comprising: a main chamber 20 for storing product objects; and a portion dispensing mechanism for dispensing a portion comprising a plurality of project objects 40. The portion dispensing mechanism comprises a gate arrangement 36 and a collection chamber 24 which are configured for relative linear movement between a loading configuration and a dispensing configuration. In the loading configuration a plurality of product objects 40 within the main chamber 20 collect within the collection chamber 24 and the gate arrangement 36 prevents product objects 40 from being dispensed from the collection chamber 24. In the dispensing configuration the gate arrangement 36 prevents product objects within the main chamber 20 from entering the collection chamber 24 and a plurality of product objects are dispensed from the collection chamber.

Abstract: The description relates to devices and device adjustment. One example can include a first portion that defines a cam pivot. The example can also include a height adjuster comprising a wedge and a positioning loop positioned over the cam pivot, such that rotation of a cam on the cam pivot to contact one cam follower of the positioning loop that moves the wedge toward another component or to contact an opposite cam follower of the positioning loop that moves the wedge away from the another component.

Abstract: Provided herein are double-stranded nucleic acid inhibitor molecules having a sense strand with a stem loop structure and an antisense strand, where the loop portion of the stem loop structure is a triloop. Also provided are methods and compositions for reducing target gene expression and methods and compositions for treating a disease of interest.

Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.